Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
This report aims to provide a comprehensive presentation of the global market for Drugs for Metabolic Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Metabolic Disorders. This report contains market size and forecasts of Drugs for Metabolic Disorders in global, including the following market information:
Global Drugs for Metabolic Disorders Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Drugs for Metabolic Disorders Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Drugs for Metabolic Disorders companies in 2022 (%)
The global Drugs for Metabolic Disorders market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Glycogen Metabolism Disease Drug Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Drugs for Metabolic Disorders include Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin and LG Life Science, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Drugs for Metabolic Disorders manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Metabolic Disorders Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Metabolic Disorders Market Segment Percentages, by Type, 2022 (%)
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
Global Drugs for Metabolic Disorders Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Metabolic Disorders Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Global Drugs for Metabolic Disorders Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Metabolic Disorders Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Metabolic Disorders revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Drugs for Metabolic Disorders revenues share in global market, 2022 (%)
Key companies Drugs for Metabolic Disorders sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Drugs for Metabolic Disorders sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Boehringer Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Metabolic Disorders, market overview.
Chapter 2: Global Drugs for Metabolic Disorders market size in revenue and volume.
Chapter 3: Detailed analysis of Drugs for Metabolic Disorders manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Metabolic Disorders in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Drugs for Metabolic Disorders capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Drugs for Metabolic Disorders Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Metabolic Disorders Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Metabolic Disorders Overall Market Size
2.1 Global Drugs for Metabolic Disorders Market Size: 2022 VS 2029
2.2 Global Drugs for Metabolic Disorders Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Drugs for Metabolic Disorders Sales: 2018-2029
3 Company Landscape
3.1 Top Drugs for Metabolic Disorders Players in Global Market
3.2 Top Global Drugs for Metabolic Disorders Companies Ranked by Revenue
3.3 Global Drugs for Metabolic Disorders Revenue by Companies
3.4 Global Drugs for Metabolic Disorders Sales by Companies
3.5 Global Drugs for Metabolic Disorders Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Drugs for Metabolic Disorders Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Drugs for Metabolic Disorders Product Type
3.8 Tier 1, Tier 2 and Tier 3 Drugs for Metabolic Disorders Players in Global Market
3.8.1 List of Global Tier 1 Drugs for Metabolic Disorders Companies
3.8.2 List of Global Tier 2 and Tier 3 Drugs for Metabolic Disorders Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Drugs for Metabolic Disorders Market Size Markets, 2022 & 2029
4.1.2 Glycogen Metabolism Disease Drug
4.1.3 Lipid Metabolism Disease Drug
4.1.4 Amino Acid Metabolism Drug
4.1.5 Other
4.2 By Type - Global Drugs for Metabolic Disorders Revenue & Forecasts
4.2.1 By Type - Global Drugs for Metabolic Disorders Revenue, 2018-2023
4.2.2 By Type - Global Drugs for Metabolic Disorders Revenue, 2024-2029
4.2.3 By Type - Global Drugs for Metabolic Disorders Revenue Market Share, 2018-2029
4.3 By Type - Global Drugs for Metabolic Disorders Sales & Forecasts
4.3.1 By Type - Global Drugs for Metabolic Disorders Sales, 2018-2023
4.3.2 By Type - Global Drugs for Metabolic Disorders Sales, 2024-2029
4.3.3 By Type - Global Drugs for Metabolic Disorders Sales Market Share, 2018-2029
4.4 By Type - Global Drugs for Metabolic Disorders Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drugs for Metabolic Disorders Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.2 By Application - Global Drugs for Metabolic Disorders Revenue & Forecasts
5.2.1 By Application - Global Drugs for Metabolic Disorders Revenue, 2018-2023
5.2.2 By Application - Global Drugs for Metabolic Disorders Revenue, 2024-2029
5.2.3 By Application - Global Drugs for Metabolic Disorders Revenue Market Share, 2018-2029
5.3 By Application - Global Drugs for Metabolic Disorders Sales & Forecasts
5.3.1 By Application - Global Drugs for Metabolic Disorders Sales, 2018-2023
5.3.2 By Application - Global Drugs for Metabolic Disorders Sales, 2024-2029
5.3.3 By Application - Global Drugs for Metabolic Disorders Sales Market Share, 2018-2029
5.4 By Application - Global Drugs for Metabolic Disorders Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Drugs for Metabolic Disorders Market Size, 2022 & 2029
6.2 By Region - Global Drugs for Metabolic Disorders Revenue & Forecasts
6.2.1 By Region - Global Drugs for Metabolic Disorders Revenue, 2018-2023
6.2.2 By Region - Global Drugs for Metabolic Disorders Revenue, 2024-2029
6.2.3 By Region - Global Drugs for Metabolic Disorders Revenue Market Share, 2018-2029
6.3 By Region - Global Drugs for Metabolic Disorders Sales & Forecasts
6.3.1 By Region - Global Drugs for Metabolic Disorders Sales, 2018-2023
6.3.2 By Region - Global Drugs for Metabolic Disorders Sales, 2024-2029
6.3.3 By Region - Global Drugs for Metabolic Disorders Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Drugs for Metabolic Disorders Revenue, 2018-2029
6.4.2 By Country - North America Drugs for Metabolic Disorders Sales, 2018-2029
6.4.3 US Drugs for Metabolic Disorders Market Size, 2018-2029
6.4.4 Canada Drugs for Metabolic Disorders Market Size, 2018-2029
6.4.5 Mexico Drugs for Metabolic Disorders Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Drugs for Metabolic Disorders Revenue, 2018-2029
6.5.2 By Country - Europe Drugs for Metabolic Disorders Sales, 2018-2029
6.5.3 Germany Drugs for Metabolic Disorders Market Size, 2018-2029
6.5.4 France Drugs for Metabolic Disorders Market Size, 2018-2029
6.5.5 U.K. Drugs for Metabolic Disorders Market Size, 2018-2029
6.5.6 Italy Drugs for Metabolic Disorders Market Size, 2018-2029
6.5.7 Russia Drugs for Metabolic Disorders Market Size, 2018-2029
6.5.8 Nordic Countries Drugs for Metabolic Disorders Market Size, 2018-2029
6.5.9 Benelux Drugs for Metabolic Disorders Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Drugs for Metabolic Disorders Revenue, 2018-2029
6.6.2 By Region - Asia Drugs for Metabolic Disorders Sales, 2018-2029
6.6.3 China Drugs for Metabolic Disorders Market Size, 2018-2029
6.6.4 Japan Drugs for Metabolic Disorders Market Size, 2018-2029
6.6.5 South Korea Drugs for Metabolic Disorders Market Size, 2018-2029
6.6.6 Southeast Asia Drugs for Metabolic Disorders Market Size, 2018-2029
6.6.7 India Drugs for Metabolic Disorders Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Drugs for Metabolic Disorders Revenue, 2018-2029
6.7.2 By Country - South America Drugs for Metabolic Disorders Sales, 2018-2029
6.7.3 Brazil Drugs for Metabolic Disorders Market Size, 2018-2029
6.7.4 Argentina Drugs for Metabolic Disorders Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Drugs for Metabolic Disorders Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Drugs for Metabolic Disorders Sales, 2018-2029
6.8.3 Turkey Drugs for Metabolic Disorders Market Size, 2018-2029
6.8.4 Israel Drugs for Metabolic Disorders Market Size, 2018-2029
6.8.5 Saudi Arabia Drugs for Metabolic Disorders Market Size, 2018-2029
6.8.6 UAE Drugs for Metabolic Disorders Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Drugs for Metabolic Disorders Major Product Offerings
7.1.4 Merck Drugs for Metabolic Disorders Sales and Revenue in Global (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Drugs for Metabolic Disorders Major Product Offerings
7.2.4 Novartis Drugs for Metabolic Disorders Sales and Revenue in Global (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Takeda Pharmaceutical
7.3.1 Takeda Pharmaceutical Company Summary
7.3.2 Takeda Pharmaceutical Business Overview
7.3.3 Takeda Pharmaceutical Drugs for Metabolic Disorders Major Product Offerings
7.3.4 Takeda Pharmaceutical Drugs for Metabolic Disorders Sales and Revenue in Global (2018-2023)
7.3.5 Takeda Pharmaceutical Key News & Latest Developments
7.4 Astra Zeneca
7.4.1 Astra Zeneca Company Summary
7.4.2 Astra Zeneca Business Overview
7.4.3 Astra Zeneca Drugs for Metabolic Disorders Major Product Offerings
7.4.4 Astra Zeneca Drugs for Metabolic Disorders Sales and Revenue in Global (2018-2023)
7.4.5 Astra Zeneca Key News & Latest Developments
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Company Summary
7.5.2 Boehringer Ingelheim Business Overview
7.5.3 Boehringer Ingelheim Drugs for Metabolic Disorders Major Product Offerings
7.5.4 Boehringer Ingelheim Drugs for Metabolic Disorders Sales and Revenue in Global (2018-2023)
7.5.5 Boehringer Ingelheim Key News & Latest Developments
7.6 KOWA
7.6.1 KOWA Company Summary
7.6.2 KOWA Business Overview
7.6.3 KOWA Drugs for Metabolic Disorders Major Product Offerings
7.6.4 KOWA Drugs for Metabolic Disorders Sales and Revenue in Global (2018-2023)
7.6.5 KOWA Key News & Latest Developments
7.7 Kythera
7.7.1 Kythera Company Summary
7.7.2 Kythera Business Overview
7.7.3 Kythera Drugs for Metabolic Disorders Major Product Offerings
7.7.4 Kythera Drugs for Metabolic Disorders Sales and Revenue in Global (2018-2023)
7.7.5 Kythera Key News & Latest Developments
7.8 Fuji yakuhin
7.8.1 Fuji yakuhin Company Summary
7.8.2 Fuji yakuhin Business Overview
7.8.3 Fuji yakuhin Drugs for Metabolic Disorders Major Product Offerings
7.8.4 Fuji yakuhin Drugs for Metabolic Disorders Sales and Revenue in Global (2018-2023)
7.8.5 Fuji yakuhin Key News & Latest Developments
7.9 LG Life Science
7.9.1 LG Life Science Company Summary
7.9.2 LG Life Science Business Overview
7.9.3 LG Life Science Drugs for Metabolic Disorders Major Product Offerings
7.9.4 LG Life Science Drugs for Metabolic Disorders Sales and Revenue in Global (2018-2023)
7.9.5 LG Life Science Key News & Latest Developments
7.10 Metsubishi Tanabe Pharma
7.10.1 Metsubishi Tanabe Pharma Company Summary
7.10.2 Metsubishi Tanabe Pharma Business Overview
7.10.3 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Major Product Offerings
7.10.4 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales and Revenue in Global (2018-2023)
7.10.5 Metsubishi Tanabe Pharma Key News & Latest Developments
8 Global Drugs for Metabolic Disorders Production Capacity, Analysis
8.1 Global Drugs for Metabolic Disorders Production Capacity, 2018-2029
8.2 Drugs for Metabolic Disorders Production Capacity of Key Manufacturers in Global Market
8.3 Global Drugs for Metabolic Disorders Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Drugs for Metabolic Disorders Supply Chain Analysis
10.1 Drugs for Metabolic Disorders Industry Value Chain
10.2 Drugs for Metabolic Disorders Upstream Market
10.3 Drugs for Metabolic Disorders Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Drugs for Metabolic Disorders Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Drugs for Metabolic Disorders in Global Market
Table 2. Top Drugs for Metabolic Disorders Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Drugs for Metabolic Disorders Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Drugs for Metabolic Disorders Revenue Share by Companies, 2018-2023
Table 5. Global Drugs for Metabolic Disorders Sales by Companies, (K Units), 2018-2023
Table 6. Global Drugs for Metabolic Disorders Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Drugs for Metabolic Disorders Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Drugs for Metabolic Disorders Product Type
Table 9. List of Global Tier 1 Drugs for Metabolic Disorders Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Metabolic Disorders Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Drugs for Metabolic Disorders Sales (K Units), 2018-2023
Table 15. By Type - Global Drugs for Metabolic Disorders Sales (K Units), 2024-2029
Table 16. By Application ? Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Drugs for Metabolic Disorders Sales (K Units), 2018-2023
Table 20. By Application - Global Drugs for Metabolic Disorders Sales (K Units), 2024-2029
Table 21. By Region ? Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Drugs for Metabolic Disorders Sales (K Units), 2018-2023
Table 25. By Region - Global Drugs for Metabolic Disorders Sales (K Units), 2024-2029
Table 26. By Country - North America Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Drugs for Metabolic Disorders Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Drugs for Metabolic Disorders Sales, (K Units), 2018-2023
Table 29. By Country - North America Drugs for Metabolic Disorders Sales, (K Units), 2024-2029
Table 30. By Country - Europe Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Drugs for Metabolic Disorders Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Drugs for Metabolic Disorders Sales, (K Units), 2018-2023
Table 33. By Country - Europe Drugs for Metabolic Disorders Sales, (K Units), 2024-2029
Table 34. By Region - Asia Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Drugs for Metabolic Disorders Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Drugs for Metabolic Disorders Sales, (K Units), 2018-2023
Table 37. By Region - Asia Drugs for Metabolic Disorders Sales, (K Units), 2024-2029
Table 38. By Country - South America Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Drugs for Metabolic Disorders Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Drugs for Metabolic Disorders Sales, (K Units), 2018-2023
Table 41. By Country - South America Drugs for Metabolic Disorders Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Drugs for Metabolic Disorders Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Drugs for Metabolic Disorders Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Drugs for Metabolic Disorders Sales, (K Units), 2024-2029
Table 46. Merck Company Summary
Table 47. Merck Drugs for Metabolic Disorders Product Offerings
Table 48. Merck Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Merck Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Drugs for Metabolic Disorders Product Offerings
Table 52. Novartis Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Novartis Key News & Latest Developments
Table 54. Takeda Pharmaceutical Company Summary
Table 55. Takeda Pharmaceutical Drugs for Metabolic Disorders Product Offerings
Table 56. Takeda Pharmaceutical Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Takeda Pharmaceutical Key News & Latest Developments
Table 58. Astra Zeneca Company Summary
Table 59. Astra Zeneca Drugs for Metabolic Disorders Product Offerings
Table 60. Astra Zeneca Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Astra Zeneca Key News & Latest Developments
Table 62. Boehringer Ingelheim Company Summary
Table 63. Boehringer Ingelheim Drugs for Metabolic Disorders Product Offerings
Table 64. Boehringer Ingelheim Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Boehringer Ingelheim Key News & Latest Developments
Table 66. KOWA Company Summary
Table 67. KOWA Drugs for Metabolic Disorders Product Offerings
Table 68. KOWA Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. KOWA Key News & Latest Developments
Table 70. Kythera Company Summary
Table 71. Kythera Drugs for Metabolic Disorders Product Offerings
Table 72. Kythera Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Kythera Key News & Latest Developments
Table 74. Fuji yakuhin Company Summary
Table 75. Fuji yakuhin Drugs for Metabolic Disorders Product Offerings
Table 76. Fuji yakuhin Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Fuji yakuhin Key News & Latest Developments
Table 78. LG Life Science Company Summary
Table 79. LG Life Science Drugs for Metabolic Disorders Product Offerings
Table 80. LG Life Science Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. LG Life Science Key News & Latest Developments
Table 82. Metsubishi Tanabe Pharma Company Summary
Table 83. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Product Offerings
Table 84. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Metsubishi Tanabe Pharma Key News & Latest Developments
Table 86. Drugs for Metabolic Disorders Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 87. Global Drugs for Metabolic Disorders Capacity Market Share of Key Manufacturers, 2021-2023
Table 88. Global Drugs for Metabolic Disorders Production by Region, 2018-2023 (K Units)
Table 89. Global Drugs for Metabolic Disorders Production by Region, 2024-2029 (K Units)
Table 90. Drugs for Metabolic Disorders Market Opportunities & Trends in Global Market
Table 91. Drugs for Metabolic Disorders Market Drivers in Global Market
Table 92. Drugs for Metabolic Disorders Market Restraints in Global Market
Table 93. Drugs for Metabolic Disorders Raw Materials
Table 94. Drugs for Metabolic Disorders Raw Materials Suppliers in Global Market
Table 95. Typical Drugs for Metabolic Disorders Downstream
Table 96. Drugs for Metabolic Disorders Downstream Clients in Global Market
Table 97. Drugs for Metabolic Disorders Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Drugs for Metabolic Disorders Segment by Type in 2022
Figure 2. Drugs for Metabolic Disorders Segment by Application in 2022
Figure 3. Global Drugs for Metabolic Disorders Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Drugs for Metabolic Disorders Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Drugs for Metabolic Disorders Revenue, 2018-2029 (US$, Mn)
Figure 7. Drugs for Metabolic Disorders Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Drugs for Metabolic Disorders Revenue in 2022
Figure 9. By Type - Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Drugs for Metabolic Disorders Revenue Market Share, 2018-2029
Figure 11. By Type - Global Drugs for Metabolic Disorders Sales Market Share, 2018-2029
Figure 12. By Type - Global Drugs for Metabolic Disorders Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Drugs for Metabolic Disorders Revenue Market Share, 2018-2029
Figure 15. By Application - Global Drugs for Metabolic Disorders Sales Market Share, 2018-2029
Figure 16. By Application - Global Drugs for Metabolic Disorders Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Drugs for Metabolic Disorders Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Drugs for Metabolic Disorders Revenue Market Share, 2018-2029
Figure 20. By Region - Global Drugs for Metabolic Disorders Sales Market Share, 2018-2029
Figure 21. By Country - North America Drugs for Metabolic Disorders Revenue Market Share, 2018-2029
Figure 22. By Country - North America Drugs for Metabolic Disorders Sales Market Share, 2018-2029
Figure 23. US Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Drugs for Metabolic Disorders Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Drugs for Metabolic Disorders Sales Market Share, 2018-2029
Figure 28. Germany Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 29. France Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Drugs for Metabolic Disorders Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Drugs for Metabolic Disorders Sales Market Share, 2018-2029
Figure 37. China Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 41. India Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Drugs for Metabolic Disorders Revenue Market Share, 2018-2029
Figure 43. By Country - South America Drugs for Metabolic Disorders Sales Market Share, 2018-2029
Figure 44. Brazil Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Drugs for Metabolic Disorders Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Drugs for Metabolic Disorders Sales Market Share, 2018-2029
Figure 48. Turkey Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Drugs for Metabolic Disorders Revenue, (US$, Mn), 2018-2029
Figure 52. Global Drugs for Metabolic Disorders Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Drugs for Metabolic Disorders by Region, 2022 VS 2029
Figure 54. Drugs for Metabolic Disorders Industry Value Chain
Figure 55. Marketing Channels
